These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [DETECTION OF MONOAMINE OXIDASE ACTIVITY AND CATECHOL O-METHYLTRANSFERASE IN THE PLASMA OF RATS POISONED WITH CARBON TETRACHLORIDE]. TRUHAUT R; AMAR A; BOHUON C Ann Biol Clin (Paris); 1964; 22():1055-65. PubMed ID: 14232090 [No Abstract] [Full Text] [Related]
27. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Muenter MD; Tyce GM Mayo Clin Proc; 1971 Apr; 46(4):231-9. PubMed ID: 5573818 [No Abstract] [Full Text] [Related]
28. COMT inhibition in Parkinson's disease: rationale and clinical relevance. Deleu D Acta Neurol Belg; 2000 Mar; 100(1):5-7. PubMed ID: 10779856 [No Abstract] [Full Text] [Related]
29. Parkinson's disease; modern treatment. Tolosa E Minn Med; 1973 Jun; 56(6):497-502. PubMed ID: 4575903 [No Abstract] [Full Text] [Related]
30. [Biochemical bases for the treatment of Parkinson's syndrome with L-dopa]. Pletscher A; Bartholini G; Gey KF; Jenni A Schweiz Med Wochenschr; 1970 May; 100(19):797-804. PubMed ID: 4924275 [No Abstract] [Full Text] [Related]
31. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease. Sternic N; Kacar A; Filipovic S; Svetel M; Kostic VS Clin Neuropharmacol; 1998; 21(2):93-6. PubMed ID: 9579294 [TBL] [Abstract][Full Text] [Related]
32. Bensarazid with L-dopa in the treatment of parkinson's disease. Van Wieringen A S Afr Med J; 1974 Feb; 48(6):206-9. PubMed ID: 4814495 [No Abstract] [Full Text] [Related]
33. Catechol-O-methyltransferase activity: a determinant of levodopa response. Reilly DK; Rivera-Calimlim L; Van Dyke D Clin Pharmacol Ther; 1980 Aug; 28(2):278-86. PubMed ID: 7398195 [TBL] [Abstract][Full Text] [Related]
34. Position of COMT inhibition in the treatment of Parkinson's disease. Gordin A; Kaakkola S; Teräväinen H Adv Neurol; 2003; 91():237-50. PubMed ID: 12442682 [No Abstract] [Full Text] [Related]
35. [Treatment of Parkinson's disease with L-dopa]. Guglielmi L; Vecchi L Clin Ter; 1970 May; 53(3):259-69. PubMed ID: 4917328 [No Abstract] [Full Text] [Related]
36. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease. Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775 [No Abstract] [Full Text] [Related]
37. Levo-dihydroxyphenylalanine--Parkinson's disease and manganese poisoning. Goldman ME IMS Ind Med Surg; 1972 Apr; 41(4):12-5. PubMed ID: 4502399 [No Abstract] [Full Text] [Related]
38. The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission. Napolitano A; Cesura AM; Da Prada M J Neural Transm Suppl; 1995; 45():35-45. PubMed ID: 8748607 [TBL] [Abstract][Full Text] [Related]
39. Rasagiline (Azilect) for Parkinson's disease. Med Lett Drugs Ther; 2006 Dec; 48(1249/1250):97-9. PubMed ID: 17149358 [No Abstract] [Full Text] [Related]
40. [L-dopa and Parkinson's disease]. Barbeau A Union Med Can; 1970 Dec; 99(12):2195-7. PubMed ID: 5488646 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]